This
article reports on the preparation and solid-state characterization
of an indomethacin–caffeine drug–drug cocrystal (or
codrug) in a 1:1 stoichiometry. These two active ingredients are frequently
coadministered as part of a therapy against strong migraines, in a
commercially available fixed dose combination formulation. The X-ray
crystal structure of the codrug is characterized by a hydrogen bond
interaction between the carboxylic moiety of indomethacin and the
purinic nitrogen atom of caffeine. The combination of multinuclear
and multidimensional solid-state NMR measurements (1H MAS, 13C and 15N CPMAS, 1H DQ MAS, 13C–1H HETCOR, 14N–1H J- and D-HMQC), as well as IR data, provided spectroscopic evidence
about the hydrogen atom position along the hydrogen bond axis, thereby
confirming the neutral nature of the cocrystal. Furthermore, dissolution
kinetic tests revealed superior bioavailability of indomethacin in
the codrug compared to indomethacin alone and to an indomethacin–caffeine
physical mixture. On the other hand, the melting point of indomethacin
was slightly lower in the cocrystal rather than in the pure drug.